Puma Biotechnology Inc (NASDAQ:PBYI) Expected to Post Earnings of -$0.52 Per Share

Brokerages expect Puma Biotechnology Inc (NASDAQ:PBYI) to announce earnings per share of ($0.52) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Puma Biotechnology’s earnings, with the highest EPS estimate coming in at ($0.44) and the lowest estimate coming in at ($0.59). Puma Biotechnology reported earnings per share of ($0.80) in the same quarter last year, which suggests a positive year-over-year growth rate of 35%. The business is scheduled to announce its next earnings report on Thursday, February 27th.

On average, analysts expect that Puma Biotechnology will report full year earnings of ($2.15) per share for the current year, with EPS estimates ranging from ($2.26) to ($2.09). For the next year, analysts expect that the business will post earnings of ($1.54) per share, with EPS estimates ranging from ($2.29) to ($1.15). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Puma Biotechnology.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.32. Puma Biotechnology had a negative net margin of 33.90% and a negative return on equity of 325.89%. The company had revenue of $56.40 million during the quarter, compared to analyst estimates of $60.21 million. During the same period last year, the firm posted $0.16 EPS. Puma Biotechnology’s revenue for the quarter was down 9.9% compared to the same quarter last year.

PBYI has been the subject of a number of recent research reports. Citigroup set a $13.00 price target on shares of Puma Biotechnology and gave the stock a “hold” rating in a research report on Monday, August 12th. BidaskClub raised shares of Puma Biotechnology from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 21st. Royal Bank of Canada dropped their price objective on shares of Puma Biotechnology to $13.00 and set a “sector perform” rating on the stock in a research note on Thursday, November 7th. Cowen reaffirmed a “hold” rating and set a $25.00 price objective on shares of Puma Biotechnology in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. reaffirmed a “sell” rating and set a $13.00 price objective on shares of Puma Biotechnology in a research note on Monday, August 12th. Four analysts have rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $14.13.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Puma Biotechnology by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 3,065,679 shares of the biopharmaceutical company’s stock worth $38,964,000 after purchasing an additional 118,785 shares during the period. Macquarie Group Ltd. grew its stake in Puma Biotechnology by 6.7% in the 2nd quarter. Macquarie Group Ltd. now owns 1,053,402 shares of the biopharmaceutical company’s stock valued at $13,389,000 after acquiring an additional 66,234 shares during the period. Millennium Management LLC grew its stake in Puma Biotechnology by 49.3% in the 3rd quarter. Millennium Management LLC now owns 677,395 shares of the biopharmaceutical company’s stock valued at $7,292,000 after acquiring an additional 223,564 shares during the period. Nuveen Asset Management LLC acquired a new stake in Puma Biotechnology in the 2nd quarter valued at $7,716,000. Finally, Rock Springs Capital Management LP grew its stake in Puma Biotechnology by 16.7% in the 2nd quarter. Rock Springs Capital Management LP now owns 534,400 shares of the biopharmaceutical company’s stock valued at $6,792,000 after acquiring an additional 76,400 shares during the period. 92.68% of the stock is currently owned by institutional investors and hedge funds.

PBYI opened at $10.73 on Tuesday. Puma Biotechnology has a 12-month low of $6.26 and a 12-month high of $43.90. The company has a current ratio of 1.71, a quick ratio of 1.67 and a debt-to-equity ratio of 6.84. The firm has a market capitalization of $418.05 million, a PE ratio of -3.59 and a beta of 1.68. The firm has a 50 day moving average of $7.93 and a two-hundred day moving average of $10.81.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).

Read More: What is the definition of a trade war?

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.